Pathalys Pharma Stock
HealthTechLooking to sell Pathalys Pharma stock or options?
Pathalys Pharma develops advanced therapeutics aimed at addressing the unmet needs of managing late-stage chronic kidney diseases. The company has created upacicalcet, a novel calcimimetic designed to enhance the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. It works by mimicking calcium's effects on tissues through activating the calcium-sensing receptor found in various human organs. This innovation allows healthcare providers to better treat patients with end-stage critical kidney disease.
The Carlyle Group, Catalys Pacific, Launch Therapeutics, KB Investment, Marshall Wace, JPMorgan Life Sciences Private Capital, TCG Crossover Management, Abingworth, Japan Post Investment, DaVita Venture Group, OrbiMed, Samsara BioCapital.